Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,535 recalls, newest first.

Class II · Moderate risk

Pirfenidone Tablets 801 mg

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-468-15 D-0420-2023
Class II · Moderate risk

Vigabatrin for Oral Solution

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-521-63 D-0418-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-372-10 D-0417-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-371-10 D-0416-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-370-10 D-0415-2023
Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-369-10 D-0414-2023
Class II · Moderate risk

Simvastatin Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-004-15 D-0409-2023
Class II · Moderate risk

Rosuvastatin Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-287-10 D-0407-2023
Class II · Moderate risk

Rosuvastatin Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-286-15 D-0406-2023
Class II · Moderate risk

Rosuvastatin Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-285-15 D-0405-2023
Class II · Moderate risk

Rosuvastatin Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-284-15 D-0404-2023

Recalls by year